# 2023

| | |
|---|---|
| | |
| | 688238.SH |

2023 20,480.50 29.69%

-12,793.83 425.90%

-13,354.89 476.11%

-9,012.18 520.65% 2023

CDMO

CGT CDMO

CGT CDMO

{2022}61

10,000.00 1.00 13.23

1,323,000,000.00

1,197,464,432.14 2022 3 22

2022 3 22 2025 12 31

2023 1 1 2023 12 31

**2023**

| | |
|---|---|
| 1 | |
| 2 | |
| 3 | |
| 4 | |
| 5 | 2024 4 20 2024 4 25 |
| | |

| | |
|---|---|
| | |
| 15 | |

16

[redacted]

| | |
|---|---|
| 15 | |
| | |
| | |
| | |
| | |
| | |

| | |
|---|---|
| | |
| | |

**1**

**2**

**1**

**2**

**3**

**1**

**2**

| | | | | |
|---|---|---|---|---|
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |

| | | | | |
|---|---|---|---|---|
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |

| | | | |
|---|---|---|---|
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |

| | | | | |
|---|---|---|---|---|
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |

| | |
|---|---|
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | **269,094,176.43** |
| | |
| | **116,094,176.43** |

| | | | | |
|---|---|---|---|---|
| 1 | 1 | | 98860078801600001960 | 114,400,577.22 |
| | | | 98860078801100001959 | 270,084.98 |
| 2 | | | 121929394110858 | - |
| | | | 121938180510616 | - |
| 3 | 2 | | 50131000890396571 | 1,423,514.23 |
| 4 | | | 2900001010120100061913 | - |
| | | - | - | **116,094,176.43** |

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | | | | | | | |
| | | 2015/12/8 | 2025/9/12 | 94,465,800 | 122,805,540 | 28,339,740 | | |
| | | 2020/10/10 | 2025/9/12 | 0 | 975,000 | 975,000 | | |
| | | 2019/12/16 | 2025/9/12 | | | | | |
| | | 2015/12/8 | 2025/9/12 | 7,118,800 | 9,254,440 | 2,135,640 | | |
| | | 2015/12/8 | 2025/9/12 | 6,723,600 | 8,740,680 | 2,017,080 | | |
| | | 2022/5/18 | 2025/9/12 | 0 | 84,500 | 84,500 | | |
| | | 2020/10/10 | 2025/9/12 | 0 | 0 | 0 | | |
| | | 2022/9/13 | 2023/12/2 | 0 | 0 | 0 | | |

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| GANGWANG | | 2020/12/29 | 2025/9/12 | 0 | 0 | 0 | | |
| | | 2020/12/29 | 2025/9/12 | 0 | 0 | 0 | | |
| | | 2020/12/29 | 2025/9/12 | 0 | 0 | 0 | | |
| | | 2021/4/2 | 2023/12/2 | 0 | 0 | 0 | | |
| | | 2020/3/20 | 2022/9/13 | 0 | 0 | 0 | | |
| | | 2022/9/13 | 2025/9/12 | | | | | |
| | | 2022/9/13 | 2025/9/12 | 0 | 0 | 0 | | |
| | | 2020/11/9 | 2025/9/12 | 0 | 0 | 0 | | |
| | | 2016/12/16 | 2025/9/12 | 0 | 650,000 | 650,000 | | |
| | | 2016/12/16 | 2025/9/12 | 5,969,600 | 7,760,480 | 1,790,880 | | |
| | | 2020/12/14 | 2025/9/12 | 0 | 455,000 | 455,000 | | |

（本页无正文，为《海通证券股份有限公司关于和元生物技术（上海）股份有限公司 2023 年度持续督导年度跟踪报告》之签字盖章页）

保荐代表人签名：

陈恒瑞　　张子慧

海通证券股份有限公司